PROTEIN DEGRADERS PREVENTION

Brand Owner (click to sort) Address Description
BIDAC C4 Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472 Protein degraders for the prevention and treatment of human diseases and conditions, namely, cancer, tumors, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, viral diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, enzyme deficiency diseases and disorders, and infectious diseases; pharmaceutical products for the prevention and treatment of cancer, tumors, autoimmune disorders, neurological, vascular and infectious diseases; pharmaceutical preparations for immunotherapy;
MONODAC C4 Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472 Protein degraders for the prevention and treatment of human diseases and conditions, namely, cancer, tumors, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, viral diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, enzyme deficiency diseases and disorders, and infectious diseases; pharmaceutical products for the prevention and treatment of cancer, tumors, autoimmune disorders, neurological, vascular and infectious diseases; pharmaceutical preparations for immunotherapy;MONO DAC;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Issues that are addressed in accordance with at least one presently preferred embodiment of the present invention, are: improvements upon the time it takes to physically swap degraders (done previously by hand); the safety involved in doing so, since the degraders become highly radioactive; possible improved energy resolution and beam stability if the accelerator can be left running continuously; and in-situ monitoring of beam current, beam position and stability. Particularly contemplated are methods and arrangements for changing degraders automatically, not manually, and in a safe manner.